Efficacy of Benfluorex in Combination with Sulfonylurea in Type 2 Diabetic Patients: an 18-week, Randomized, Double-blind Study.
From: Endocrinology Department, Cardiovascular Hospital, University Claude Bernard, Lyon, France. philippe.moulin@chu-lyon.fr
Diabetes care
- Publish Date: Mar 2006
- ISSN: 0149-5992
- Volume: 29
- Issue: 3
- Pages: 515-20
- Medium: Print
- Language: English
- Citation (JAMA): Moulin Philippe, Andre Marie, Alawi Hasan, et al. Efficacy of Benfluorex in Combination with Sulfonylurea in Type 2 Diabetic Patients: an 18-week, Randomized, Double-blind Study.. Diabetes Care Mar 2006;29:515-20
Abstract
OBJECTIVE: The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add-on therapy in type 2 diabetic patients in whom diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin. RESEARCH DESIGN AND METHODS: Type 2 diabetic patients with HbA(1c) (A1C) (7-10%) who were receiving the maximum tolerated sulfonylurea dose and had a contraindication to or poor tolerance of metformin were randomly assigned (double blind) to receive benfluorex 450 mg/day (n = 165) or placebo (n = 160) for 18 weeks. The main efficacy criterion was A1C, analyzed as the change from baseline to the end of treatment using ANCOVA with baseline and country as covariates. Secondary criteria were fasting plasma glucose (FPG), insulin resistance, and plasma lipid level. RESULTS: Both groups were similar at baseline in the intention-to-treat population. A1C significantly decreased with benfluorex from 8.34 +/- 0.83 to 7.52 +/- 1.04% (P < 0.001) and tended to increase with placebo from 8.33 +/- 0.87 to 8.52 +/- 1.36% (NS), resulting in a mean adjusted difference between groups of -1.01% (95% CI -1.26 to -0.76; P < 0.001). The target A1C (< or =7%) was achieved in 34% of patients receiving benfluorex versus 12% of patients receiving placebo. Significant between-group differences in favor of benfluorex were observed for mean FPG (-1.65 mmol/l) (P < 0.001) and for homeostasis model assessment of insulin resistance. Overall tolerance was similar in both groups. Serious adverse events were more frequent in the benfluorex group, without evidence of causality relationship. CONCLUSIONS: Benfluorex as an add-on therapy was superior to placebo in lowering A1C with a between-group difference of 1% in type 2 diabetic patients whose disease was insufficiently controlled with sulfonylurea alone and in whom metformin was contraindicated or not tolerated.
Mesh Headings (Keywords): Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Fenfluramine, Hemoglobin A, Glycosylated, Humans, Male, Middle Aged, Sulfonylurea Compounds
Check for Full Text / PubMed Unique Identifier (PMID): 16505498
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.